Status:
COMPLETED
A Study on the Efficacy and Safety of IPyC for HER2+ MBC
Lead Sponsor:
Fujian Medical University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progre...
Eligibility Criteria
Inclusion
- patients who underwent a biopsy of the metastatic site and were confirmed as having MBC
- patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy.
Exclusion
- male patients or individuals with prior malignancy
- patients with prior or current enrollment in interventional clinical trials for MBC
- patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib)
- patients who were lost to follow-up during the therapeutic process
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT06990347
Start Date
July 1 2020
End Date
May 1 2025
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fujian Cancer Hospital
Fuzhou, China